NDAINJECTIONINJECTABLE
Approved
May 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
FUROSEMIDE (furosemide) by Fresenius Kabi is henle. First approved in 1984.
Drug data last refreshed 8m ago · AI intelligence enriched 6h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Furosemide is a loop diuretic administered via injection that acts on the ascending limb of the loop of Henle to inhibit sodium and chloride reabsorption, producing potent diuresis. It is indicated for patients requiring rapid fluid removal in acute decompensated heart failure, pulmonary edema, and edematous states associated with renal or hepatic disease. The injectable formulation enables use in acute care settings where rapid onset is critical.
LOE Approaching
As a 40-year-old injectable generic with LOE approaching, the product faces commodity pricing pressure and is likely managed by a lean team focused on supply chain and generic cost management rather than growth initiatives.
Mechanism of Action
Henle. The high degree of efficacy is largely due to this unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone.
Pharmacologic Class:
Loop Diuretic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Bumetanide vs. Furosemide in Cirrhosis
Started Jun 2026
500 enrolled
Cirrhosis
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Started Mar 2026
41 enrolled
Healthy
Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
Started Feb 2026
16 enrolled
Healthy
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
Started Aug 2024
32 enrolled
Healthy
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
Started Jul 2024
91 enrolled
Healthy Participants
Worked on FUROSEMIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.